Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review Richardson JD; Fikretoglu D; Liu A; McIntosh DBMC Psychiatry 2011[May]; 11 (ä): 86BACKGROUND: In this chart review, we attempted to evaluate the benefits of adding aripiprazole in veterans with military-related PTSD and comorbid depression, who had been minimally or partially responsive to their existing medications. METHODS: A retrospective chart review of patients who received an open-label, flexible-dose, 12- week course of adjunctive aripiprazole was conducted in 27 military veterans meeting DSM-IV criteria for PTSD and comorbid major depression. Concomitant psychiatric medications continued unchanged, except for other antipsychotics which were discontinued prior to initiating aripiprazole. The primary outcome variable was a change from baseline in the PTSD checklist-military version (PCL-M) and the Beck Depression Inventory (BDI-II). RESULTS: PTSD severity (Total PCL scores) decreased from 56.11 at baseline to 46.85 at 12-weeks (p < 0.0001 from Wilcoxon signed rank test) and the depression severity decreased from 30.44 at baseline to 20.67 at 12-weeks (p < 0.0001 from Wilcoxon signed rank test). Thirty seven percent (10/27) were considered responders, as defined by a decrease in total PCL scores of at least 20 percent and 19% (5/27) were considered as responders as defined by a decrease in total BDI score of at least 50%. CONCLUSIONS: The addition of aripiprazole contributed to a reduction in both PTSD and depression symptomatology in a population that has traditionally demonstrated poor pharmacological response. Further investigations, including double-blind, placebo-controlled studies, are essential to confirm and further demonstrate the benefit of aripiprazole augmentation in the treatment of military related PTSD.|Adult[MESH]|Antipsychotic Agents/therapeutic use[MESH]|Aripiprazole[MESH]|Depressive Disorder, Major/complications/*drug therapy[MESH]|Drug Resistance/*drug effects[MESH]|Drug Therapy, Combination/*psychology[MESH]|Female[MESH]|Humans[MESH]|Male[MESH]|Piperazines/*therapeutic use[MESH]|Psychiatric Status Rating Scales/statistics & numerical data[MESH]|Psychotropic Drugs/therapeutic use[MESH]|Quinolones/*therapeutic use[MESH]|Retrospective Studies[MESH]|Stress Disorders, Post-Traumatic/complications/*drug therapy[MESH]|Veterans/*psychology[MESH] |
